| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 25 |
| 1 | TACROLIMUS | 12 |
| 2 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 12 |
| 3 | TACROLIMUS OINTMENT 0.1% | 12 |
| 4 | CARBOPLATIN | 11 |
| 5 | CYCLOPHOSPHAMIDE | 11 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 11 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 11 |
| 8 | NIVOLUMAB | 11 |
| 9 | IPILIMUMAB | 8 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TREMELIMUMAB | 2 | 0.0005 |
| 1 | MESNA INJECTION | 3 | 0.0004 |
| 2 | MESNA | 3 | 0.0004 |
| 3 | THIOTEPA | 3 | 0.0003 |
| 4 | GAUNFACINE | 1 | 0.0003 |
| 5 | GILTERITINIB | 1 | 0.0002 |
| 6 | PEMBROLIZUMAB | 25 | 0.0002 |
| 7 | AMOXICILLIN AND CLAVULANATE POTASSIUM | 1 | 0.0002 |
| 8 | IPILIMUMAB | 8 | 0.0002 |
| 9 | VALGANCICLOVIR | 3 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 36 | 0.0004 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 10 | 0.0002 |
| 2 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 3 | 0.0001 |
| 3 | Thrombopoietin Receptor Agonist [EPC] | 2 | 0.0001 |
| 4 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |
| 5 | Programmed Death Ligand-1 Blocker [EPC] | 2 | 0.0001 |
| 6 | Alkylating Drug [EPC] | 12 | 0.0000 |
| 7 | BCL-2 Inhibitor [EPC] | 3 | 0.0000 |
| 8 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 1 | 0.0000 |
| 9 | Calcineurin Inhibitor Immunosuppressant [EPC] | 6 | 0.0000 |